LAVAL, Quebec, April 23, 2014 /CNW/ - Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today its nominees to stand for election to the Board of Directors at its annual meeting of shareholders on May 20, 2014.
Quebec-based Valeant Pharmaceuticals International Inc. said Monday it intends to propose a merger with California-based Allergan, using a combination of stock and cash, with the cash portion worth �around $15-billion,� according to U.S.
Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.
Valeant Pharmaceuticals Intl Inc logo Valeant Pharmaceuticals Intl (NYSE:BVF) was upgraded by equities researchers at TD Securities from a �hold� rating to a �buy� rating in a research report issued on Wednesday, American Banking News reports.
The unlikely teaming up of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Allergan's single largest shareholder, will see Allergan's shareholders getting $48.30 in cash and and 0.83 percent in Valeant stock for each share they own, according to a ...
In a cash-and-stock deal valued at $45.7 billion, Valeant Pharmaceuticals Inc. would give Allergan investors $48.30 in cash and 0.83 percent in Valeant stock for each share they own. Pershing Square Capital Management LP, the fund run by Bill Ackman, ...
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide.